PDCD1 and cancer: Subsequently, cemiplimab (Libtayo®, Regeneron, Tarrytown, NY, USA), dostarlimab (Jemperli®, GlaxoSmithKline, Brentford, UK), toripalimab (Loqtorzi®, Coherus Bioscience, Redwood City, CA, USA), and tislelizumab (Tevimbra®, BeiGene, Cambridge, MA, USA) have been approved by the FDA as PD-1 binders for cancer treatment.